Labcorp price target raised to $285 from $270 at Baird

Baird analyst Eric Coldwell raised the firm’s price target on Labcorp to $285 from $270 and keeps an Outperform rating on the shares. The analyst said while the company’s comments/positioning around CRO haven’t always aligned with results, the tone remains largely upbeat and the NHP situation appears less daunting than first feared.